STOCK TITAN

HUTCHMED (HCM) deputy CFO details options and share holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

HUTCHMED (China) Ltd Deputy Chief Financial Officer Lorenso Chiu has filed an initial Form 3 detailing his equity interests in the company. He reports multiple share options over American depositary shares with exercise prices between $10.7500 and $27.9400, vesting over four years and expiring between 2030 and 2033. He also holds Long Term Incentive Plan awards over 8,108 ordinary shares indirectly through a plan trustee, plus 46,007 ordinary shares and 8,475 American depositary shares directly. Each American depositary share represents five ordinary shares.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Chiu Lorenso

(Last)(First)(Middle)
C/O 48TH FLOOR, CHEUNG KONG CENTER, 2
QUEEN'S ROAD CENTRAL

(Street)
HONG KONG00000

(City)(State)(Zip)

HONG KONG

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
HUTCHMED (China) Ltd [ HCM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Deputy Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares46,007D
American depositary shares(1)8,475D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy)(2)04/28/202004/27/2030American depositary shares17,700$22.09(3)D
Share option (right to buy)(2)03/26/202103/25/2031American depositary shares7,120$27.94(3)D
Share option (right to buy)(2)05/23/202205/22/2032American depositary shares16,400$10.75(3)D
Share option (right to buy)(2)06/05/202306/04/2033American depositary shares3,000$12.51(3)D
Long Term Incentive Plan awards granted on 08/05/2024 (4) (4)ordinary shares8,108(4)IHeld by Long Term Incentive Plan trustee
Explanation of Responses:
1. Each American depositary share represents 5 ordinary shares.
2. The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options.
3. The exercise price for the share option is denominated in United States dollar per American depositary share.
4. All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026.
/s/ Lorenso Chiu03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the HUTCHMED (HCM) Form 3 filing by Lorenso Chiu show?

The Form 3 shows Lorenso Chiu’s existing HUTCHMED equity holdings, including options over American depositary shares, Long Term Incentive Plan awards, and directly held ordinary shares and ADSs. It is an initial ownership report, not a record of new trades.

How many HUTCHMED share options does Lorenso Chiu report on Form 3?

Lorenso Chiu reports four share option grants over American depositary shares, with underlying amounts of 17,700, 7,120, 16,400 and 3,000 ADS. These options have exercise prices between $10.7500 and $27.9400 and expire from 2030 to 2033.

What direct HUTCHMED share holdings does Lorenso Chiu disclose on Form 3?

He discloses 46,007 ordinary shares and 8,475 American depositary shares held directly. These positions sit alongside his option grants and incentive awards, giving a clear picture of his current direct equity stake in HUTCHMED.

How are HUTCHMED American depositary shares related to ordinary shares?

Each HUTCHMED American depositary share represents five ordinary shares, according to the footnotes. This ratio helps investors understand how ADS-based option grants and direct ADS holdings translate into the company’s underlying ordinary share capital structure.

What Long Term Incentive Plan awards are reported for HUTCHMED Deputy CFO Lorenso Chiu?

The filing reports 8,108 ordinary shares under a Long Term Incentive Plan, held indirectly by a plan trustee. Footnotes state these awards will vest in 2027, three weeks after completion of the share purchase for the financial year ending December 31, 2026.
Hutchmed (China) Limited

NASDAQ:HCM

View HCM Stock Overview

HCM Rankings

HCM Latest News

HCM Latest SEC Filings

HCM Stock Data

2.45B
174.47M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Hong Kong
CAMBRIDGE